On the afternoon of July 3, 2024, Ha Tay Pharmaceutical (DHT) had the honor of welcoming Mr. Takashi Yamaguchi, Chairman of ASKA Pharmaceutical, one of Japan’s leading pharmaceutical corporations, for a visit in celebration of Hataphar’s High-Tech Pharmaceutical Plant receiving the GMP certification for “Good Manufacturing Practices for drugs and drug ingredients.”
This event is particularly significant, marking the close and long-term cooperative relationship between Hataphar and ASKA Pharmaceutical. The visit spanned two consecutive days with many meaningful activities.
During the visit, Mr. Takashi Yamaguchi was introduced to the modern production processes, featuring advanced machinery and equipment at Hataphar’s High-Tech Pharmaceutical Plant—an essential project in the collaboration between Ha Tay Pharmaceutical and ASKA. The two sides engaged in in-depth discussions about future development directions, with a commitment to even closer cooperation to deliver high-quality, safe, and effective products to Vietnamese consumers.
ASKA Pharmaceutical, a strategic partner of Ha Tay Pharmaceutical, is ranked among the Top 20 pharmaceutical companies in Japan, with a history of over 100 years. The company operates a Japan-GMP-certified plant specializing in products for internal medicine, obstetrics, gynecology, and urology, trusted in the Japanese market and many countries worldwide.
Ha Tay Pharmaceutical firmly believes that with close cooperation with ASKA Pharmaceutical, the company will continue to develop and achieve even greater success in the future. This collaboration will enhance Hataphar’s production capabilities and product quality, meeting the demands of both domestic and international pharmaceutical markets. The long-term goal is to position Ha Tay Pharmaceutical as a leading manufacturer in Vietnam, gradually expanding into the regional and global markets.
